Figure 1.

Reasons for the discontinuation of mold-active triazoles in the prophylaxis subgroup (safety analysis set). Patients could have been counted in multiple categories but were only counted once for each category. ^aPercentages are derived from the number of patients without missing data in each category; isavuconazole n = 245, posaconazole n = 368, voriconazole n = 267, multiple/sequenced MATs n = 252, and total n = 1132. ^bLack of efficacy was reported for a patient who received MAT prophylaxis, developed a bIFD, and then switched to a new MAT for treatment. ^c“Other” reasons for discontinuation of MATs included but were not limited to hospital visits, hospital admission, discharge, lack of intravenous formulation, and inpatient and outpatient switching. ^dMultiple/sequenced MATs described patients receiving >1 MAT for prophylaxis throughout the study since index/enrollment. Abbreviations: bIFD, breakthrough invasive fungal infection; MAT, mold-active triazole.